Dr. Ethan Morgan is a Neuroscience & Peptide Research Specialist and medical author for Neuro Peptides. He has more than 10 years of experience in scientific research, medical education, and evidence-based content focused on: Neuroscience and brain health Peptide research Neurobiology Cellular signaling and molecular research Educational Background Dr. Morgan received formal training in biomedical sciences and neuroscience, with a focus on molecular biology, cellular signaling, and research-based approaches to understanding neurological processes. For more than 10 years, he has worked with scientific literature and medical research, translating complex findings into clear and accessible educational content. His work focuses on helping readers understand emerging research involving peptides, cellular pathways, neurobiology, and related areas of biomedical science. Research Focus Areas Dr. Morgan’s primary research interests include neuroscience, peptide biology, cellular communication, and molecular mechanisms involved in neurological and physiological processes. His work involves reviewing scientific literature on research peptides and examining how specific peptides are being investigated in preclinical and clinical research. He focuses on presenting established findings separately from emerging or preliminary evidence. He does not promote the use of unapproved medicines or research peptides in humans. His content is intended for educational and research purposes only. Approach to Scientific Education Dr. Morgan believes that scientific information should be accurate, understandable, and supported by credible research. His approach is to break down complex studies and explain important findings in straightforward language without overstating what the available evidence shows. Through his writing for Neuro Peptides, he aims to help readers better understand peptide research, neuroscience, molecular biology, and emerging developments in biomedical science.
If you recently tried to visit PureRx Peptides and could not access the website, you may be wondering what happened. For some users, the website may not be accessible at all, while others may see a static screen stating: ” We are no longer operating”. PureRx Peptides has permanently ceased operations. We sincerely thank all […]
Retatrutide and semaglutide differ mainly in how they interact with hormone receptors in the body. Semaglutide activates one primary target, the GLP-1 receptor. Retatrutide activates three: the GLP-1, GIP, and glucagon receptors. For this reason, semaglutide is called a single GLP-1 receptor agonist, while retatrutide is known as a triple receptor agonist. This difference is […]
Retatrutide has gained significant attention owing to its distinctive way of action. Drugs like semaglutide work through the GLP-1 receptor pathway only. However, retatrutide works on all three metabolic receptors at once – GLP-1, GIP, and glucagon. This gives it a broader pharmacological profile than a GLP-1-only drug. Coskun et al. described LY3437943, the compound […]
Retatrutide has emerged as one of the most highly anticipated substances in metabolic studies in 2026. The reason for the high level of interest lies in the unique mechanism of action of retatrutide, which suggests that Retatrutide agonizes three receptors: the GIP receptor, GLP-1 receptor, and glucagon receptor. In this well researched blog, we will […]
Things in the peptide market are not going well for companies selling research peptides in the gray market. A few major peptide vendors, including Peptide Sciences and Science.bio, have already closed their operations. Now, Strate Labs has also started winding down its business, leaving many former customers looking for other sources for their research needs. […]
Retatrutide is an investigational peptide known as a triple hormone receptor agonist. The term “triple” simply means that retatrutide is designed to activate three different hormone receptors instead of targeting only one. These three receptors are the GLP-1 receptor (GLP-1R), GIP receptor (GIPR), and glucagon receptor (GCGR). Each receptor is involved in metabolic processes such […]
Retatrutide (LY3437943), developed by Eli Lilly and Company, is an investigational peptide currently not approved for human consumption and is under investigation. It works by targeting three hormone receptors: This unique triple-action mechanism makes it different from the rest of the peptides that have been developed for the treatment of various metabolic disorders. There have […]
Peptides have been the subject of increasing research, and two peptides that are often mentioned together despite many differences are BPC-157 and TB-500. So, what is the difference between BPC-157 and TB-500? In what areas do they share similarities? We will find out here. What is BPC-157? BPC-157 refers to an artificial peptide fragment linked […]
